2022
Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Current Oncology Reports 2022, 24: 1741-1750. PMID: 36255606, PMCID: PMC10878124, DOI: 10.1007/s11912-022-01338-5.Peer-Reviewed Original ResearchConceptsLocoregional therapyIntrahepatic cholangiocarcinomaManagement of ICCFuture prospective randomized studiesComparable survival outcomesSafety of hepatectomyProspective Randomized StudyLocal tumor controlNon-surgical approachCurrent clinical practicePurpose of reviewUnresectable diseaseSurgical candidatesSystemic therapyVenous embolizationRandomized studyTransarterial embolizationDismal prognosisMultimodal treatmentSafety profileSurvival outcomesAblative therapyTumor controlPreoperative hypertrophyLiver lobeKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 71-90. PMID: 34991070, PMCID: PMC10191161, DOI: 10.6004/jnccn.2022.0001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaStage IV renal cell carcinomaNCCN guidelinesKidney cancerTreatment selectionNCCN Clinical Practice GuidelinesAdvanced renal cell carcinomaSystemic therapy recommendationsFirst-line treatmentPre-existing comorbiditiesClinical practice guidelinesKidney cancer therapyRecommended regimensSystemic therapyRisk stratificationTumor histologyCell carcinomaTreatment recommendationsTherapy recommendationsRisk groupsPractice guidelinesCancer fociTherapy selectionCancer panelPatients
2020
Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
Aslam A, Gian R, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World Journal Of Hepatology 2020, 12: 738-753. PMID: 33200013, PMCID: PMC7643220, DOI: 10.4254/wjh.v12.i10.738.Peer-Reviewed Original ResearchTreatment response algorithmLI-RADS treatment response algorithmLocoregional therapyLiver Imaging ReportingHepatocellular carcinomaTreatment response assessmentTreatment optionsResponse assessmentData System treatment response algorithmImaging ReportingDifferent locoregional therapiesLiver transplant candidacyHCC treatment responseTransplant candidacyOverall survivalSystemic therapyTumor burdenLeading causeTreatment responseLI-RADSTumor assessmentEconomic burdenClinical practiceTumor progressionTherapyEmbolotherapy for Hepatic Oncology: Current Perspectives and Future Directions
Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Digestive Disease Interventions 2020, 04: 134-147. PMID: 32832829, PMCID: PMC7437993, DOI: 10.1055/s-0040-1712146.Peer-Reviewed Original ResearchSecondary liver tumorsLiver tumorsTransarterial liver-directed therapiesLocoregional treatment strategiesLiver-directed therapiesSecondary liver cancerSelective internal radiotherapyHepatic oncologySystemic therapyBland embolizationTreatment strategiesLiver cancerInternal radiotherapyMajor causeEmbolotherapyTherapyTumorsCurrent perspectivesSupportive evidenceModalitiesChemoembolizationEmbolizationRadiotherapyCancerMortality
2007
Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab
Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. Journal Of Vascular And Interventional Radiology 2007, 18: 1588-1591. PMID: 18057297, DOI: 10.1016/j.jvir.2007.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCetuximabColorectal NeoplasmsCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsColorectal cancerTreatment experienceAdvanced unresectable colorectal cancerUnresectable colorectal cancerMetastatic colorectal cancerCohort of patientsYttrium-90 microspheresSystemic therapyBiologic agentsDrug AdministrationHepatic neoplasiaCetuximabPatientsCancerBevacizumabChemotherapyNeoplasiaTherapyCohortPhysiciansAdministration
2006
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval